Access the full text.
Sign up today, get DeepDyve free for 14 days.
Jian-hua Wang, Zexing Wang, Yunzhao Zhao (2015)Incidence and Risk of Hypertension with Ramucirumab in Cancer Patients: A Meta-Analysis of Published Studies
Clinical Drug Investigation, 35
M. Maitland, G. Bakris, H. Black, Helen Chen, J. Durand, W. Elliott, S. Ivy, C. Leier, J. Lindenfeld, Glenn Liu, S. Remick, R. Steingart, W. Tang (2010)Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors
JNCI Journal of the National Cancer Institute, 102
M. Azizi, A. Chedid, S. Oudard (2008)Home blood-pressure monitoring in patients receiving sunitinib.
The New England journal of medicine, 358 1
Tatsuro Yamaguchi, H. Bando, Takeo Mori, Keiichi Takahashi, H. Matsumoto, M. Yasutome, H. Weich, M. Toi (2007)Overexpression of soluble vascular endothelial growth factor receptor 1 in colorectal cancer: Association with progression and prognosis
Cancer Science, 98
W. Qi, Zan Shen, Lina Tang, Yang Yao (2014)Risk of Hypertension in Cancer Patients Treated with Aflibercept: A Systematic Review and Meta-Analysis
Clinical Drug Investigation, 34
R. Tio, J. Wijpkema, E. Tan, F. Asselbergs, G. Hospers, G. Jessurun, F. Zijlstra (2005)Reduction of endothelial dysfunction following VEGF gene therapy.
Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation, 13 4
D. Pinkhas, T. Ho, Sakima Smith (2017)Assessment of pazopanib-related hypertension, cardiac dysfunction and identification of clinical risk factors for their development
Thomas Hutson, V. Lesovoy, S. Al-Shukri, V. Stus, O. Lipatov, A. Bair, B. Rosbrook, Connie Chen, S. Kim, N. Vogelzang (2013)Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
The Lancet. Oncology, 14 13
Rixe (2007)Hypertension as a predictive factor of Sunitinib activity
Ann Oncol, 18
R. Midgley, D. Kerr (2005)Bevacizumab--current status and future directions.
Annals of oncology : official journal of the European Society for Medical Oncology, 16 7
B. Escudier, M. Gore (2011)Axitinib for the Management of Metastatic Renal Cell Carcinoma
Drugs in R&D, 11
H. Izzedine, C. Massard, J. Spano, F. Goldwasser, D. Khayat, J. Soria (2010)VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management.
European journal of cancer, 46 2
M. Rajabi, S. Mousa (2017)The Role of Angiogenesis in Cancer Treatment
Fei Dai, Lixing Shu, Yangfang Bian, Zhuo Wang, Zhangwei Yang, W. Chu, Shen Gao (2013)Safety of Bevacizumab in Treating Metastatic Colorectal Cancer: A Systematic Review and Meta-analysis of All Randomized Clinical Trials
Clinical Drug Investigation, 33
O. Mir, R. Coriat, S. Ropert, Laure Cabanes, B. Blanchet, S. Camps, B. Billemont, B. Knebelmann, F. Goldwasser (2012)Treatment of bevacizumab-induced hypertension by amlodipine
Investigational New Drugs, 30
D. Keefe, J. Bowen, R. Gibson, T. Tan, M. Okera, A. Stringer (2011)Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review.
The oncologist, 16 4
R. Motzer, B. Escudier, P. Tomczak, Thomas Hutson, M. Michaelson, S. Négrier, S. Oudard, M. Gore, J. Tarazi, S. Hariharan, Connie Chen, B. Rosbrook, S. Kim, B. Rini (2013)Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
The Lancet. Oncology, 14 6
A. Milan, E. Puglisi, L. Ferrari, G. Bruno, I. Losano, F. Veglio (2014)Arterial hypertension and cancer
International Journal of Cancer, 134
Yan Li, Shun Li, Yaofeng Zhu, Xinyue Liang, Hui Meng, Jun Chen, Dongqing Zhang, Hu Guo, B. Shi (2014)Incidence and Risk of Sorafenib‐Induced Hypertension: A Systematic Review and Meta‐Analysis
The Journal of Clinical Hypertension, 16
V. Ranpura, Bhargava Pulipati, D. Chu, Xiaolei Zhu, Shenhong Wu (2010)Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis.
American journal of hypertension, 23 5
I. Sousa, J. Ferreira, J. Rodrigues, N. Bonito, P. Jacinto, M. Marques, J. Ribeiro, A. Pais, H. Gervásio (2016)Association between bevacizumab-related hypertension and response to treatment in patients with metastatic colorectal cancer
ESMO Open, 1
E. Eisenhauer, P. Therasse, J. Bogaerts, L. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, Lawrence Rubinstein, L. Shankar, L. Dodd, Robert Kaplan, D. Lacombe, J. Verweij (2009)New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
European journal of cancer, 45 2
F. Gurevich, M. Perazella (2009)Renal effects of anti-angiogenesis therapy: update for the internist.
The American journal of medicine, 122 4
Kerbel (2008)Tumor angiogenesis
N Engl J Med, 358
J. Frampton (2016)Lenvatinib: A Review in Refractory Thyroid Cancer
Targeted Oncology, 11
W. Qi, Aina He, Zan Shen, Yang Yao (2013)Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis.
British journal of clinical pharmacology, 76 3
C. Chung, Nisha Pherwani (2013)Ziv-aflibercept: a novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 70 21
T. Choueiri, B. Escudier, T. Powles, P. Mainwaring, B. Rini, F. Donskov, H. Hammers, Thomas Hutson, Jae-Lyun Lee, K. Peltola, B. Roth, G. Bjarnason, L. Geczi, B. Keam, P. Maroto, D. Heng, M. Schmidinger, P. Kantoff, A. Borgman-Hagey, C. Hessel, C. Scheffold, G. Schwab, N. Tannir, R. Motzer (2015)Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.
The New England journal of medicine, 373 19
Zexing Wang, Jing Xu, Weiwei Nie, Guichun Huang, Jin-hai Tang, X. Guan (2013)Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis
European Journal of Clinical Pharmacology, 70
S. Koch, L. Claesson-Welsh (2012)Signal transduction by vascular endothelial growth factor receptors.
Cold Spring Harbor perspectives in medicine, 2 7
J. Mourad, G. Guetz, H. Debbabi, B. Levy (2008)Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation.
Annals of oncology : official journal of the European Society for Medical Oncology, 19 5
B. Dreyfus, H. Kawabata, A. Gomez (2013)Selected adverse events in cancer patients treated with vascular endothelial growth factor inhibitors.
Cancer epidemiology, 37 2
B. Barleon, P. Reusch, F. Totzke, Christel Herzog, C. Keck, G. Martiny-Baron, D. Marmé (2004)Soluble VEGFR-1 secreted by endothelial cells and monocytes is present in human serum and plasma from healthy donors
S. Wilhelm, J. Dumas, Lila Adnane, M. Lynch, Christopher Carter, G. Schütz, K. Thierauch, D. Zopf (2011)Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
International Journal of Cancer, 129
M. Schlumberger, M. Tahara, L. Wirth (2015)Lenvatinib in radioiodine-refractory thyroid cancer.
The New England journal of medicine, 372 19
Yihai Cao, J. Arbiser, R. D'Amato, P. D’Amore, D. Ingber, R. Kerbel, M. Klagsbrun, Sharon Lim, M. Moses, B. Zetter, H. Dvorak, R. Langer (2011)Forty-Year Journey of Angiogenesis Translational Research
Science Translational Medicine, 3
B. Rini, T. Rouge, A. Harzstark, M. Michaelson, Glenn Liu, V. Grünwald, A. Ingrosso, Michael Tortorici, P. Bycott, S. Kim, Joanna Bloom, R. Motzer (2013)Five-year survival in patients with cytokine-refractory metastatic renal cell carcinoma treated with axitinib.
Clinical genitourinary cancer, 11 2
M. Schlumberger, M. Tahara, L. Wirth, B. Robinson, M. Brose, R. Elisei, M. Habra, K. Newbold, M. Shah, A. Hoff, A. Gianoukakis, N. Kiyota, Matthew Taylor, Sung-Bae Kim, M. Krzyzanowska, C. Dutcus, B. Heras, Junming Zhu, S. Sherman (2015)Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
The New England journal of medicine, 372 7
P. Bono, P. Bono, Heidi Elfving, T. Utriainen, P. Österlund, T. Saarto, T. Alanko, H. Joensuu, H. Joensuu (2008)Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology, 20 2
F. Thibault, H. Izzedine, B. Billemont, G. Deray, O. Rixe (2007)Hypertension as a predictive factor of Sunitinib activity.
Annals of oncology : official journal of the European Society for Medical Oncology, 18 6
J. Folkman (1971)Tumor angiogenesis: therapeutic implications.
The New England journal of medicine, 285 21
Vinicius Souza, Eduardo Silva, M. Ribeiro, W. Martins (2015)Hypertension in Patients with Cancer
Arquivos Brasileiros de Cardiologia, 104
B. Nazer, B. Humphreys, J. Moslehi (2011)Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension.
Circulation, 124 15
V. Eremina, J. Jefferson, J. Kowalewska, H. Hochster, M. Haas, J. Weisstuch, C. Richardson, J. Kopp, M. Kabir, P. Backx, H. Gerber, N. Ferrara, L. Barisoni, C. Alpers, S. Quaggin (2008)VEGF inhibition and renal thrombotic microangiopathy.
The New England journal of medicine, 358 11
F. Dong, Xiaochun Zhang, L. Wold, Qun Ren, Zhaojie Zhang, Jun Ren (2005)Endothelin‐1 enhances oxidative stress, cell proliferation and reduces apoptosis in human umbilical vein endothelial cells: role of ETB receptor, NADPH oxidase and caveolin‐1
British Journal of Pharmacology, 145
M. Langenberg, C. Herpen, J. Bono, J. Schellens, C. Unger, K. Hoekman, H. Blum, W. Fiedler, J. Drevs, F. Maulf, A. Fielding, J. Robertson, E. Voest (2009)Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 36
J. Rautiola, F. Donskov, K. Peltola, H. Joensuu, P. Bono (2016)Sunitinib‐induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma
BJU International, 117
J. Zamorano, P. Lancellotti, Daniel Muñoz, V. Aboyans, R. Asteggiano, M. Galderisi, G. Habib, D. Lenihan, G. Lip, A. Lyon, T. Fernández, D. Mohty, M. Piepoli, J. Tamargo, A. Torbicki, T. Suter (2016)2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC).
European heart journal, 37 36
Lixin Li, G. Fink, S. Watts, C. Northcott, J. Galligan, P. Pagano, Alex Chen (2003)Endothelin-1 Increases Vascular Superoxide via EndothelinA–NADPH Oxidase Pathway in Low-Renin Hypertension
Circulation: Journal of the American Heart Association, 107
J. Zamorano, P. Lancellotti, Daniel Muñoz, V. Aboyans, R. Asteggiano, M. Galderisi, G. Habib, D. Lenihan, G. Lip, A. Lyon, T. Fernández, D. Mohty, M. Piepoli, J. Tamargo, A. Torbicki, T. Suter, S. Achenbach, S. Agewall, L. Badimón, G. Barón-Esquivias, H. Baumgartner, Jeroen Bax, H. Bueno, S. Carerj, V. Dean, Ç. Erol, D. Fitzsimons, O. Gaemperli, P. Kirchhof, P. Kolh, P. Nihoyannopoulos, P. Ponikowski, M. Roffi, A. Carneiro, S. Windecker (2016)2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
European Journal of Heart Failure, 19
Emily Robinson, E. Khankin, S. Karumanchi, S. Karumanchi, Benjamin Humphreys, Benjamin Humphreys (2010)Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker.
Seminars in nephrology, 30 6
Masakazu Toi, H. Bando, Taeko Ogawa, M. Muta, Carsten Hornig, H. Weich (2002)Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor‐1 relationship in breast cancer
International Journal of Cancer, 98
F. Worden, M. Fassnacht, Yuankai Shi, T. Hadjieva, F. Bonichon, M. Gao, L. Fugazzola, Y. Ando, Y. Hasegawa, D. Park, Y. Shong, J. Smit, J. Chung, C. Kappeler, G. Meinhardt, M. Schlumberger, M. Brose (2015)Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer
Endocrine-Related Cancer, 22
K. Bible, V. Suman, J. Molina, R. Smallridge, W. Maples, M. Menefee, J. Rubin, N. Karlin, K. Sideras, J. Morris, B. Mciver, I. Hay, V. Fatourechi, J. Burton, Kevin Webster, C. Bieber, A. Traynor, P. Flynn, Boon Goh, C. Isham, P. Harris, C. Erlichman (2014)A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H.
The Journal of clinical endocrinology and metabolism, 99 5
Xiaolei Zhu, K. Stergiopoulos, Shenhong Wu (2009)Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis
Acta Oncologica, 48
A. Pande, J. Lombardo, E. Spangenthal, M. Javle (2007)Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab.
Anticancer research, 27 5B
O. Hamnvik, T. Choueiri, A. Turchin, R. McKay, L. Goyal, Michael Davis, M. Kaymakcalan, Jonathan Williams (2015)Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway
S. Winnik, C. Lohmann, G. Siciliani, Tobias Lukowicz, K. Kuschnerus, N. Kraenkel, C. Brokopp, F. Enseleit, S. Michels, F. Ruschitzka, T. Lüscher, C. Matter (2013)Systemic VEGF inhibition accelerates experimental atherosclerosis and disrupts endothelial homeostasis--implications for cardiovascular safety.
International journal of cardiology, 168 3
H. Small, A. Montezano, F. Rios, C. Savoia, R. Touyz (2014)Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome.
The Canadian journal of cardiology, 30 5
Simon Aad, M. Pierce, Guido Barmaimon, F. Farhat, A. Benjo, E. Mouhayar (2015)Hypertension induced by chemotherapeutic and immunosuppresive agents: a new challenge.
Critical reviews in oncology/hematology, 93 1
T. Funakoshi, A. Latif, M. Galsky (2013)Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis
Journal of Human Hypertension, 27
Loretta Fala (2015)Lenvima (Lenvatinib), a Multireceptor Tyrosine Kinase Inhibitor, Approved by the FDA for the Treatment of Patients with Differentiated Thyroid Cancer.
American health & drug benefits, 8 Spec Feature
Naoyo Nishida, H. Yano, T. Nishida, T. Kamura, M. Kojiro (2006)Angiogenesis in Cancer
Vascular Health and Risk Management, 2
Shenhong Wu, John Chen, A. Kudelka, Janice Lu, Xiaolei Zhu (2008)Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis.
The Lancet. Oncology, 9 2
S. Hayman, N. Leung, J. Grande, V. Garovic (2012)VEGF Inhibition, Hypertension, and Renal Toxicity
Current Oncology Reports, 14
R. Elisei, M. Schlumberger, S. Müller, P. Schöffski, M. Brose, M. Shah, L. Licitra, B. Jarzab, V. Medvedev, M. Kreissl, B. Niederle, E. Cohen, L. Wirth, H. Ali, C. Hessel, Y. Yaron, D. Ball, B. Nelkin, S. Sherman (2013)Cabozantinib in progressive medullary thyroid cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 29
F. Amraoui, L. Spijkers, H. Lahsinoui, L. Vogt, J. Post, S. Peters, G. Afink, C. Ris-Stalpers, B. Born (2014)SFlt-1 Elevates Blood Pressure by Augmenting Endothelin-1-Mediated Vasoconstriction in Mice
PLoS ONE, 9
S. Wells, B. Robinson, R. Gagel, H. Dralle, J. Fagin, M. Santoro, E. Baudin, R. Elisei, B. Jarzab, J. Vasselli, Jessica Read, P. Langmuir, A. Ryan, M. Schlumberger (2012)Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 2
C. Tourneau, E. Raymond, S. Faivre (2007)Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST)
Therapeutics and Clinical Risk Management, 3
S. Maynard, J. Min, J. Merchan, K. Lim, Jianyi Li, S. Mondal, T. Libermann, J. Morgan, F. Sellke, I. Stillman, F. Epstein, V. Sukhatme, S. Karumanchi (2003)Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia
Journal of Clinical Investigation, 111
G. Roviello, C. Pacifico, P. Corona, D. Generali (2017)Risk of hypertension with ramucirumab-based therapy in solid tumors: data from a literature based meta-analysis
Investigational New Drugs, 35
Carsten Hornig, B. Barleon, Shakil Ahmad, P. Vuorela, Asif Ahmed, H. Weich (2000)Release and Complex Formation of Soluble VEGFR-1 from Endothelial Cells and Biological Fluids
Laboratory Investigation, 80
P. Whelton, R. Carey, W. Aronow, D. Casey, Karen Collins, C. Himmelfarb, Sondra Depalma, S. Gidding, K. Jamerson, Daniel Jones, E. MacLaughlin, P. Muntner, B. Ovbiagele, Sidney Smith, Crystal Spencer, R. Stafford, S. Taler, Randal Thomas, K. Williams, J. Williamson, J. Wright (2018)2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Journal of the American College of Cardiology, 71 19
M. Kappers, J. Esch, W. Sluiter, S. Sleijfer, A. Danser, A. Meiracker (2010)Hypertension Induced by the Tyrosine Kinase Inhibitor Sunitinib Is Associated With Increased Circulating Endothelin-1 Levels
M. Veronese, Ari Mosenkis, K. Flaherty, M. Gallagher, J. Stevenson, R. Townsend, P. O'dwyer (2006)Mechanisms of hypertension associated with BAY 43-9006.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 9
Loretta Fala (2015)Cyramza (Ramucirumab) Approved for the Treatment of Advanced Gastric Cancer and Metastatic Non-Small-Cell Lung Cancer.
American health & drug benefits, 8 Spec Feature
H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, W. Heim, J. Berlin, A. Baron, S. Griffing, E. Holmgren, N. Ferrara, G. Fyfe, B. Rogers, R. Ross, F. Kabbinavar (2004)Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
The New England journal of medicine, 350 23
D. Cella, J. Beaumont (2016)Pazopanib in the treatment of advanced renal cell carcinoma
Therapeutic Advances in Urology, 8
Richard Kendall, Guan Wang, Kenneth Thomas (1996)Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR.
Biochemical and biophysical research communications, 226 2
Arterial hypertension (HT) is one of the most frequently recorded comorbidities among patients under antiangiogenic therapy. Inhibitors of vascular endothelial growth factor and vascular endothelial growth factor receptors are most commonly involved in new onset or exacerbation of pre-existing controlled HT. From the pathophysiology point of view, data support that reduced nitric oxide release and sodium and fluid retention, microvascular rarefaction, elevated vasoconstrictor levels, and globular injury might contribute to HT. The purpose of this review was to present recent evidence regarding the incidence of HT induced by antiangiogenic agents, to analyze the pathophysiological mechanisms, and to summarize current recommendations for the management of elevated blood pressure in this field.
American Journal of Hypertension – Oxford University Press
Published: Aug 3, 2018
Keywords: blood pressure; cancer; angiogenesis; chemotherapy; hypertension
Access the full text.
Sign up today, get DeepDyve free for 14 days.